As of 11 a.m. ET, shares of Novo Nordisk (NYSE: NVO) are down 4.2%, and Hims & Hers Health (NYSE: HIMS) stock is getting walloped for a 5.8% loss. In contrast, shares of Viking Therapeutics ...

Novo Nordisk (NVO) announced Friday that its popular ... at a higher dose of 7.2 mg in a late-stage trial. Citing topline data from its STEP-UP Phase 3b study, the Danish drugmaker said that ...

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) fell 3.6% on Friday after the U.S. Department of Health and Human Services (HHS) announced that Ozempic and Wegovy are among 15 medications ...

After Novo Nordisk (NVO) reported results from its Phase ... BofA analyst Sachin Jain called the data “a double edged sword.” The high-dose results lift the efficacy of semaglutide as ...

After Novo Nordisk (NVO) reported results from its Phase ... The firm, which believes the data highlights the potential superiority of Viking’s dual GLP-1/GIP receptor agonist VK2735 over ...

A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest Eli Lilly’s rival GLP-1 ...

Wintriss Controls Group has added flexible and affordable purchase options for ShopFloorConnect OEE, Production Tracking, and Data Collection software, which allows users to quickly and easily ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk (NOVOb.CO), opens new tab, which generates more than half of its sales in the United States. Novo ...

Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, hopes to double the size of its recently acquired contract drugmaker Catalent over five ...